Danaher (DHR) Stock Forecast & Price Target

$199.15 +2.44 (+1.24%)

Closing price 05/2/2025 03:59 PM Eastern

Extended Trading

$198.44 -0.71 (-0.36%)

As of 04:00 AM Eastern

Danaher - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 20 Analyst Ratings

Sell
0

Hold
4

Buy
16

Based on 20 Wall Street analysts who have issued ratings for Danaher in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 4 have given a hold rating, and 16 have given a buy rating for DHR.

Consensus Price Target

$264.40
32.76% Upside

According to the 20 analysts' twelve-month price targets for Danaher, the average price target is $264.40. The highest price target for DHR is $315.00, while the lowest price target for DHR is $215.00. The average price target represents a forecasted upside of 32.76% from the current price of $199.15.

Get the Latest News and Ratings for DHR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Danaher and its competitors.

DHR Analyst Ratings Over Time

Type	Current Forecast 5/5/24 to 5/5/25	1 Month Ago 4/5/24 to 4/5/25	3 Months Ago 2/5/24 to 2/4/25	1 Year Ago 5/6/23 to 5/5/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	16 Buy rating(s)	17 Buy rating(s)	15 Buy rating(s)	9 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	6 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$264.40	$278.24	$278.00	$267.31
Forecasted Upside	32.76% Upside	53.37% Upside	29.27% Upside	7.62% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

DHR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DHR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Danaher Stock vs. The Competition

Type	Danaher	Medical Companies	S&P 500
Consensus Rating Score	2.80	2.81	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	32.76% Upside	3,338.15% Upside	17.54% Upside
News Sentiment Rating	Positive News See Recent DHR News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/23/2025	Royal Bank of Canada 3 of 5 stars	Conor McNamara Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$250.00 ➝ $250.00	+25.71%
4/23/2025	The Goldman Sachs Group 3 of 5 stars	M. Sykes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$260.00 ➝ $240.00	+20.47%
4/23/2025	Guggenheim 2 of 5 stars	S. Nambi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$250.00 ➝ $250.00	+25.19%
4/23/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Dan Leonard Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$275.00 ➝ $240.00	+17.66%
4/23/2025	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Catherine Schulte Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$231.00 ➝ $225.00	+17.15%
4/22/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Tycho Peterson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$260.00 ➝ $230.00	+19.75%
4/22/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Tycho Peterson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$280.00 ➝ $260.00	+35.37%
4/22/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Sergott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$205.00 ➝ $215.00	+11.94%
4/7/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy
3/14/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Daniel Arias Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$260.00	+27.48%
Get the Latest News and Ratings for DHR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Danaher and its competitors with MarketBeat's FREE daily newsletter.
2/3/2025	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Cooper Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
1/30/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Couillard Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$280.00 ➝ $240.00	+7.57%
12/23/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Nam Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Perform	$265.00	+15.95%
12/13/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$290.00 ➝ $290.00	+23.67%
10/31/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Schenkel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$285.00	+17.61%
10/23/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$310.00 ➝ $315.00	+23.29%
10/23/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Johnson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$315.00 ➝ $315.00	+23.29%
10/23/2024	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$290.00 ➝ $310.00	+19.45%
10/1/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	V. Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$275.00 ➝ $278.00	+1.41%
7/24/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$275.00 ➝ $280.00	+5.22%
4/17/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$250.00 ➝ $280.00	+16.93%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 05:13 AM ET.

Should I Buy Danaher Stock? DHR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, April 29, 2025. Please send any questions or comments about these Danaher pros and cons to contact@marketbeat.com.

Danaher
Bull Case

Here are some ways that investors could benefit from investing in Danaher Co.:

Danaher Co. recently reported strong quarterly earnings, with earnings per share of $1.88, surpassing analyst expectations significantly, indicating robust financial health.
The company has a solid revenue stream, generating $5.74 billion in the latest quarter, which exceeded analyst estimates, showcasing its ability to perform well in the market.
Danaher Co. has increased its quarterly dividend to $0.32 per share, reflecting a commitment to returning value to shareholders, which can be attractive for income-focused investors.
The current stock price is around $197.85, which may present a buying opportunity for investors looking to enter at a favorable valuation.
With a consensus target price of $264.40 from analysts, there is potential for significant upside in the stock price, making it an appealing investment prospect.

Danaher
Bear Case

Investors should be bearish about investing in Danaher Co. for these reasons:

The stock has experienced volatility, with a 52-week high of $281.70 and a low of $171.00, indicating potential risks associated with price fluctuations.
Analysts have mixed ratings, with five holding a "hold" rating, suggesting that some investors may be cautious about the stock's future performance.
Danaher Co. has a relatively high P/E ratio of 37.47, which may indicate that the stock is overvalued compared to its earnings, posing a risk for new investors.
The company has a beta of 0.86, suggesting it is less volatile than the market, but this could also mean it may not perform as well during market upswings.
Insider selling activity, such as the recent sale of shares by a senior vice president, could raise concerns about the company's future prospects and insider confidence.

DHR Forecast - Frequently Asked Questions

: According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Danaher is $264.40, with a high forecast of $315.00 and a low forecast of $215.00.
: 20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Danaher in the last year. There are currently 4 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DHR shares.
: According to analysts, Danaher's stock has a predicted upside of 32.76% based on their 12-month stock forecasts.
: Over the previous 90 days, Danaher's stock had 3 upgrades by analysts.
: Danaher has been rated by research analysts at Barclays, Citigroup, Guggenheim, Jefferies Financial Group, JPMorgan Chase & Co., Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, The Goldman Sachs Group, and UBS Group in the past 90 days.
: Analysts like Danaher less than other "medical" companies. The consensus rating score for Danaher is 2.80 while the average consensus rating score for "medical" companies is 2.81. Learn more on how DHR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:DHR) was last updated on 5/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Danaher (DHR) Stock Forecast & Price Target